GPR20 | Clinical Trials Search

63 results for “GPR20”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

132 participants · First posted Sep 15, 2017

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

36 participants · First posted Dec 11, 2017

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

30 participants · First posted Feb 27, 2019

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

First posted Aug 1, 2019

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

38 participants · First posted Oct 29, 2020

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

42 participants · First posted Jun 16, 2021

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa

5,404 participants · First posted Nov 21, 2016

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

48 participants · First posted Aug 31, 2001

Not yet recruiting

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

126 participants · First posted Jun 30, 2026

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

117 participants · First posted Jul 18, 2017

Page 1 of 3